{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:28:49Z","timestamp":1787678929542,"version":"build-2784847793"},"reference-count":118,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.phrs.2011.06.013","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T09:40:41Z","timestamp":1309081241000},"page":"614-623","source":"Crossref","is-referenced-by-count":66,"title":["The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease"],"prefix":"10.1016","volume":"64","author":[{"given":"Thomas J.","family":"Federici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2011.06.013_bib0005","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1021\/ja01642a064","article-title":"The structure of aureomycin","volume":"76","author":"Stephens","year":"1954","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.phrs.2011.06.013_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/08959374980120011901","article-title":"Chemical and biological dynamics of tetracyclines","volume":"12","author":"Nelson","year":"1998","journal-title":"Adv Dent Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0015","first-page":"80","article-title":"Host modulation with tetracyclines and their chemically modified analogues","volume":"2","author":"Golub","year":"1992","journal-title":"Curr Opin Dent"},{"key":"10.1016\/j.phrs.2011.06.013_bib0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracylines: nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0025","first-page":"742","article-title":"Systemic tetracyclines in the treatment of noninfected corneal ulcers: a case report and proposed new mechanism of action","volume":"17","author":"Perry","year":"1985","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archopht.1978.03910050373015","article-title":"Osmolarity of tear microvolumes in keratoconjunctivitis sicca","volume":"96","author":"Gilbard","year":"1978","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0035","first-page":"475","article-title":"The scientific context and basis of the pharmacologic management of dry eyes","volume":"18","author":"Gilbard","year":"2005","journal-title":"Ophthalmol Clin N Am"},{"key":"10.1016\/j.phrs.2011.06.013_bib0040","article-title":"Hyperosmolarity stimulates production of MMp-9, IL-1\u03b2 and TNF by human corneal epithelial cells via a c-Jun NH2-terminal kinase pathway","volume":"43","author":"Li","year":"1981","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0045","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 activates MAPK signaling pathways on the ocular surface","volume":"45","author":"Luo","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0050","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ICL.0000162759.79740.46","article-title":"Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface","volume":"31","author":"Luo","year":"2005","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.phrs.2011.06.013_bib0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.exer.2006.02.004","article-title":"Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye","volume":"83","author":"De Paiva","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0060","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1167\/iovs.05-1281","article-title":"Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline","volume":"47","author":"De Paiva","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0065","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/ICO.0b013e3181757997","article-title":"Desiccation stress decreases apical corneal epithelial cell size\u2014modulation by the metalloproteinase inhibitor doxcycline","volume":"27","author":"Beardsley","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1167\/iovs.04-0929","article-title":"Doxycycline inhibits TGF-\u03b21-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells","volume":"46","author":"Kim","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bjo.2003.025551","article-title":"Doxycycline\u2014a role in ocular surface repair","volume":"88","author":"Smith","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-5751-6-11","article-title":"Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjogren's Syndrome: a randomized, double-blind, placebo controlled cross-over study","volume":"6","author":"Seitsalo","year":"2007","journal-title":"J Negat Results Biomed"},{"key":"10.1016\/j.phrs.2011.06.013_bib0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.exer.2003.09.019","article-title":"Functional aspects of the tear film lipid layer","volume":"78","author":"Bron","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0161-6420(82)34669-2","article-title":"Classification of chronic blepharitis","volume":"89","author":"McCulley","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00003226-199603000-00002","article-title":"Model for ocular tear film function","volume":"15","author":"Mathers","year":"1996","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00003226-199607000-00002","article-title":"Meibomian gland triglyceride fatty acid differences in chronic blepharitis patients","volume":"15","author":"Shine","year":"1996","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bjo.2007.133900","article-title":"Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment","volume":"92","author":"Souchier","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","article-title":"The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction","volume":"19","author":"Yoo","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0115","first-page":"336","article-title":"The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis)","volume":"106","author":"Macsai","year":"2008","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.phrs.2011.06.013_bib0120","first-page":"2970","article-title":"The role of tetracycline in chronic blepharitis: inhibition of lipase production in Staphylococci","volume":"32","author":"Dougherty","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0125","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/bjo.2006.091579","article-title":"Short term oral minocycline treatment of meibomianitis","volume":"90","author":"Aronowicz","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0130","first-page":"1477","article-title":"Acne and acneiform dermatoses","volume":"vol. 2","author":"Tolman","year":"1992"},{"key":"10.1016\/j.phrs.2011.06.013_bib0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0039-6257(86)90034-2","article-title":"Ocular rosacea","volume":"31","author":"Browning","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0140","first-page":"112","article-title":"The ocular manifestations of rosacea","volume":"68","author":"Tanzi","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.phrs.2011.06.013_bib0145","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0161-6420(97)30015-3","article-title":"Ocular rosacea: patient characteristics and follow-up","volume":"104","author":"Akpek","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/bjo.66.6.386","article-title":"Oxytetracycline in the treatment of ocular rosacea: a double-blind trial","volume":"66","author":"Bartholomew","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1997.03890370055009","article-title":"Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline","volume":"133","author":"Quarterman","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajo.2006.06.047","article-title":"Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics","volume":"142","author":"Cetinkaya","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003226-200401000-00020","article-title":"Oral tetracyclines for ocular rosacea: an evidence-based review of the literature","volume":"23","author":"Stone","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0170","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00003226-200005000-00003","article-title":"Tetracyclines and the treatment of corneal stromal ulceration: a review","volume":"19","author":"Ralph","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0600","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/archopht.1987.01060020122043","article-title":"Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits","volume":"105","author":"Seedor","year":"1987","journal-title":"Arch Ophthalmol"},{"issue":"Suppl.","key":"10.1016\/j.phrs.2011.06.013_bib0185","first-page":"208","article-title":"Topical tetracycline in the treatment of alkali-induced corneal ulceration in the rabbit","volume":"27","author":"Szmyd","year":"1986","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0190","first-page":"1569","article-title":"Inhibition of purified collagenase from alkali-burned rabbit corneas","volume":"30","author":"Burns","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0195","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0161-6420(86)33570-X","article-title":"Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects","volume":"93","author":"Perry","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.ico.0000220767.73660.3a","article-title":"The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization","volume":"25","author":"Peyman","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.ico.0000220768.11778.60","article-title":"Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model","volume":"25","author":"Riazi-Esfahani","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0210","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":"Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.phrs.2011.06.013_bib0215","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/02713680802245772","article-title":"Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis","volume":"33","author":"Dan","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1096\/fj.04-1837com","article-title":"Gelatinase B\/matrix metalloproteinase-9 provokes cataract by cleaving lens \u03b2B1 crystallin","volume":"19","author":"Deschamps","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2011.06.013_bib0225","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1167\/iovs.03-1336","article-title":"Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the human lens: implications for cortical cataract formation","volume":"45","author":"Sachdev","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2353\/ajpath.2006.041089","article-title":"Matrix metalloproteinase inhibitors suppress transforming growth factor-\u03b2-induced subcapsular cataract formation","volume":"168","author":"Dwivedi","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1076\/ceyr.19.3.269.5316","article-title":"Matrix metalloproteinase secretion is stimulated by TFG-\u03b2 in cultured lens epithelial cells","volume":"19","author":"Richiert","year":"1999","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0240","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/17469899.2.6.931","article-title":"Matrix metalloproteinases as mediators of primary and secondary cataracts","volume":"2","author":"West-Mays","year":"2007","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1999.tb07692.x","article-title":"MMP-mediated events in diabetes","volume":"878","author":"Ryan","year":"1999","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0250","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0002-9394(98)00280-3","article-title":"Diabetes, cardiovascular disease, selected cardiovascular risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0255","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archopht.122.4.525","article-title":"Risk factors for the incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies","volume":"122","author":"Hennis","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0260","series-title":"Ophthalmology","first-page":"511","article-title":"Retinal and choroidal circulation","author":"Schubert","year":"2004"},{"key":"10.1016\/j.phrs.2011.06.013_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0270","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0420.2006.00659.x","article-title":"Ocular angiogenesis: the role of growth factors","volume":"84","author":"Kvanta","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.phrs.2011.06.013_bib0275","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8","volume":"88","author":"The Diabetic Retinopathy Study Group","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0280","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Treatment Group","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0002-9440(10)63952-1","article-title":"Leukocyte-mediated endothelial cell injury and death in the diabetic retina","volume":"158","author":"Joussen","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0290","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0002-9394(01)01269-7","article-title":"Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema","volume":"133","author":"Funatsu","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0295","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1523\/JNEUROSCI.15-11-07712.1995","article-title":"Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte","volume":"15","author":"Giulian","year":"1995","journal-title":"J Neurosci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0165-5728(89)90167-7","article-title":"Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system","volume":"21","author":"Streit","year":"1989","journal-title":"J Neuroimmmunol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0305","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cne.902680209","article-title":"Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin","volume":"268","author":"Streit","year":"1988","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0310","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2337\/diabetes.54.5.1559","article-title":"Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy","volume":"54","author":"Krady","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.06.013_bib0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuint.2005.04.018","article-title":"Minocycline inhibits LPS-induced retinal microglia activation","volume":"47","author":"Wang","year":"2005","journal-title":"Neurochem Int"},{"key":"10.1016\/j.phrs.2011.06.013_bib0320","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2337\/db06-0427","article-title":"Inhibition of caspase-1\/interleukin-1\u03b2 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia","volume":"56","author":"Vincent","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.06.013_bib0325","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0968-0004(97)01085-2","article-title":"Caspases: killer proteases","volume":"22","author":"Nicholson","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0330","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2337\/diabetes.51.4.1172","article-title":"Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients","volume":"51","author":"Mohr","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.06.013_bib0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1517\/13543784.13.3.189","article-title":"Potential new strategies to prevent the development of diabetic retinopathy","volume":"13","author":"Mohr","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.phrs.2011.06.013_bib0340","first-page":"534","article-title":"High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells","volume":"24","author":"Hao","year":"2003","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.phrs.2011.06.013_bib0345","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hh1201.092042","article-title":"Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress","volume":"88","author":"Uemura","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0350","first-page":"809","article-title":"Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes","volume":"40","author":"Das","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0355","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/archopht.117.4.498","article-title":"Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor","volume":"117","author":"Das","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0360","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1167\/iovs.02-0662","article-title":"Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy","volume":"33","author":"Noda","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0365","first-page":"181","article-title":"Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats","volume":"2","author":"Bhatt","year":"2010","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0370","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ajo.2007.06.025","article-title":"Age-related macular degeneration and the immune response: implications for therapy","volume":"144","author":"Nussenblatt","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: aetiology, pathogenesis, and therapeutic strategies","volume":"48","author":"Ambati","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0380","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J Genet"},{"key":"10.1016\/j.phrs.2011.06.013_bib0385","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00006982-200604000-00012","article-title":"MMp-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules fond in choroidal neovascular membranes","volume":"26","author":"Hoffman","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.phrs.2011.06.013_bib0390","first-page":"2194","article-title":"Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes","volume":"39","author":"Steen","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0395","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1076\/0271-3683(200009)2131-RFT684","article-title":"Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization","volume":"21","author":"Kvanta","year":"2000","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0400","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.phrs.2011.06.013_bib0405","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1167\/iovs.08-3174","article-title":"Doxycycline-mediated inhibition of choroidal neovascularization","volume":"50","author":"Samtani","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0410","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1126\/science.270.5239.1189","article-title":"Fas ligand-induced apoptosis as a mechanism of immune privilege","volume":"270","author":"Griffith","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.phrs.2011.06.013_bib0415","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.4049\/jimmunol.169.9.4739","article-title":"TRAIL: a mechanism of tumor surveillance in an immune privileged site","volume":"169","author":"Lee","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0420","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.cdd.4400891","article-title":"Fas-ligand and immune privilege: the eyes have it","volume":"8","author":"Feguson","year":"2001","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.phrs.2011.06.013_bib0425","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/6509","article-title":"Fas ligand (CD95 ligand) controls angiogenesis beneath the retina","volume":"5","author":"Kaplan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.phrs.2011.06.013_bib0430","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1167\/iovs.09-3890","article-title":"Targeting immune privilege to prevent pathogenic neovascularization","volume":"51","author":"Roychoudhury","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0435","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","author":"Senger","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.phrs.2011.06.013_bib0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jcb.240470305","article-title":"The vascular endothelial growth factor family of polypeptides","volume":"47","author":"Ferrara","year":"1991","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.phrs.2011.06.013_bib0445","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1242\/jcs.108.6.2369","article-title":"Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor","volume":"108","author":"Robers","year":"1995","journal-title":"J Cell Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0450","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00941723","article-title":"Expressioin of vascular endothelial growth factor in experimental choroidal neovascularization","volume":"235","author":"Ishibashi","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0455","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01739641","article-title":"Vascular endothelial growth factor expression in choroidal neovascularization in rats","volume":"235","author":"Yi","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0460","first-page":"3158","article-title":"VEGF is a mojo stimulator in model of choroidal neovascularization","volume":"41","author":"Kwak","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0465","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment","volume":"120","author":"Krzystolik","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0470","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2011.06.013_bib0475","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/bjo.66.12.745","article-title":"Treatment of senile disciform macular degeneration: a single-blind randomized trial by argon laser photocoagulation","volume":"66","author":"The Moorfields Macular Study Group","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0480","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archopht.1982.01030030920003","article-title":"Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial","volume":"100","author":"Macular Photocoagulation Study Group","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0485","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/archopht.1986.01050170084028","article-title":"Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials","volume":"104","author":"Macular Photocoagulation Study Group","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0490","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1","volume":"117","author":"Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0495","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2","volume":"119","author":"Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0500","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0505","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1167\/iovs.02-1115","article-title":"Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF) receptor 3, and pigment epithelial derived growth factor","volume":"44","author":"Schmidt-Erfurth","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.phrs.2011.06.013_bib0510","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2011.06.013_bib0515","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial","volume":"92","author":"Singerman","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0520","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2011.06.013_bib0525","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2011.06.013_bib0530","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment for better- or worse-seeing eye. Clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0535","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.jcbfm.9600268","article-title":"Dose response effects on cerebral matrix metalloproteinases-9 after vascular endothelial growth factor hyperstimulation","volume":"26","author":"Lee","year":"2006","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.phrs.2011.06.013_bib0540","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2006.05.004","article-title":"Chemically modified tetracyclines inhibit VEGF secretion by breast cancer cell lines","volume":"35","author":"Kothari","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2011.06.013_bib0545","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1096\/fj.08-110494","article-title":"Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability","volume":"22","author":"Fainaru","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.phrs.2011.06.013_bib0550","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ophtha.2010.01.037","article-title":"Doxycycline's effect on ocular angiogenesis: an in vivo analysis","volume":"117","author":"Cox","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2011.06.013_bib0555","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000322363","article-title":"A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration","volume":"225","author":"Sivaprasad","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.phrs.2011.06.013_bib0560","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Group","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0565","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archopht.122.4.487","article-title":"Prevalence of cataract and pseudophakia\/aphakia among adults in the United States","volume":"122","author":"The Eye Diseases Prevalence Group","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0570","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"The Eye Diseases Prevalence Group","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0575","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2010.1111","article-title":"Prevalence of diabetic retinopathy in the United States, 2005\u20132008","volume":"304","author":"Zhang","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2011.06.013_bib0580","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.phrs.2011.06.013_bib0585","first-page":"473","article-title":"Vision and quality-of-life","volume":"97","author":"Brown","year":"1999","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.phrs.2011.06.013_bib0590","first-page":"927","article-title":"Tetracycline suppresses metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen ameliorates bone damage","volume":"19","author":"Greenwald","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.phrs.2011.06.013_bib0595","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1902\/jop.2004.75.3.453","article-title":"Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug","volume":"75","author":"Lee","year":"2004","journal-title":"J Periodontol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T20:37:06Z","timestamp":1637959026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661811001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":118,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1043661811001903"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2011.06.013","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}